

Sabine Siesling

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2525764/publications.pdf>

Version: 2024-02-01

153
papers

6,379
citations

109321

35
h-index

76900

74
g-index

156
all docs

156
docs citations

156
times ranked

9928
citing authors

#	ARTICLE	IF	CITATIONS
1	Needs and preferences of breast cancer survivors regarding outcome-based shared decision-making about personalised post-treatment surveillance. <i>Journal of Cancer Survivorship</i> , 2023, 17, 1471-1479.	2.9	13
2	Patient involvement in clinical pathway development, implementation and evaluation – A scoping review of international literature. <i>Patient Education and Counseling</i> , 2022, 105, 1441-1448.	2.2	8
3	Impact of COVID-19 and suspension of colorectal cancer screening on incidence and stage distribution of colorectal cancers in the Netherlands. <i>European Journal of Cancer</i> , 2022, 161, 38-43.	2.8	28
4	Adverse health effects after breast cancer up to 14 years after diagnosis. <i>Breast</i> , 2022, 61, 22-28.	2.2	15
5	Fewer head and neck cancer diagnoses and faster treatment initiation during COVID-19 in 2020: A nationwide population-based analysis. <i>Radiotherapy and Oncology</i> , 2022, 167, 42-48.	0.6	23
6	Response to –Head and neck cancer diagnoses and faster treatment initiation during COVID-19: Correspondence–. <i>Radiotherapy and Oncology</i> , 2022, , .	0.6	0
7	Using guideline-based clinical decision support in oncological multidisciplinary team meetings: A prospective, multicenter concordance study. <i>International Journal for Quality in Health Care</i> , 2022, 34, .	1.8	5
8	Socioeconomic status and its relation with breast cancer recurrence and survival in young women in the Netherlands. <i>Cancer Epidemiology</i> , 2022, 77, 102118.	1.9	3
9	Systematic Review of Health Economic Evaluations Focused on Artificial Intelligence in Healthcare: The Tortoise and the Cheetah. <i>Value in Health</i> , 2022, 25, 340-349.	0.3	23
10	Impact of the COVID-19 Pandemic on Colorectal Cancer Care in the Netherlands: A Population-based Study. <i>Clinical Colorectal Cancer</i> , 2022, 21, e171-e178.	2.3	11
11	Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 2361-2374.	1.6	45
12	Health care professionals overestimate the risk for locoregional recurrences after breast cancer treatment depending on their specialty. <i>Breast Cancer Research and Treatment</i> , 2022, , 1.	2.5	1
13	Impact of the COVID-19 outbreak on prostate cancer care in the Netherlands. <i>Cancer Treatment and Research Communications</i> , 2022, 31, 100553.	1.7	11
14	The impact of the COVID-19 pandemic on bladder cancer care in the Netherlands. <i>Bladder Cancer</i> , 2022, , 1-17.	0.4	2
15	Representativeness of trial participants: linking the EORTC boost-no boost trial to the Netherlands Cancer Registry. <i>Journal of Clinical Epidemiology</i> , 2022, , .	5.0	0
16	Associations of hospital volume and hospital competition with short-term, middle-term and long-term patient outcomes after breast cancer surgery: a retrospective population-based study. <i>BMJ Open</i> , 2022, 12, e057301.	1.9	0
17	Surgeons’s™ preferences for using sentinel lymph node biopsy in patients with ductal carcinoma in situ. <i>PLoS ONE</i> , 2022, 17, e0269551.	2.5	0
18	Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival. <i>Breast</i> , 2022, 65, 110-115.	2.2	5

#	ARTICLE	IF	CITATIONS
19	Comprehensive trends in incidence, treatment, survival and mortality of first primary invasive breast cancer stratified by age, stage and receptor subtype in the Netherlands between 1989 and 2017. <i>International Journal of Cancer</i> , 2021, 148, 2289-2303.	5.1	34
20	Socioeconomic status significantly contributes to the likelihood of immediate postmastectomy breast reconstruction in the Netherlands: A nationwide study. <i>European Journal of Surgical Oncology</i> , 2021, 47, 245-250.	1.0	7
21	Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 817-830.	2.5	2
22	Perceived Care and Well-being of Patients With Cancer and Matched Norm Participants in the COVID-19 Crisis. <i>JAMA Oncology</i> , 2021, 7, 279.	7.1	56
23	Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab010.	2.9	21
24	Cognitive Bias Modification Training to Improve Implicit Vitality in Patients With Breast Cancer: App Design Using a Cocreation Approach. <i>JMIR Formative Research</i> , 2021, 5, e18325.	1.4	4
25	Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study. <i>Journal of Hematology and Oncology</i> , 2021, 14, 64.	17.0	61
26	Prediction of Other-Cause Mortality in Older Patients with Breast Cancer Using Comorbidity. <i>Cancers</i> , 2021, 13, 1627.	3.7	7
27	New Frontiers for Fairer Breast Cancer Care in a Globalized World. <i>The Journal of Breast Health</i> , 2021, 17, 86-94.	1.0	3
28	Trends and variations in treatment of stage III non-small cell lung cancer from 2008 to 2018: A nationwide population-based study from the Netherlands. <i>Lung Cancer</i> , 2021, 155, 103-113.	2.0	14
29	Lean DIEP flap surgery: saving time and reducing complications. <i>European Journal of Plastic Surgery</i> , 2021, 44, 793-800.	0.6	1
30	Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1506-1514.	6.3	6
31	The association of socioeconomic status on treatment strategy in patients with stage I and II breast cancer in the Netherlands. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 541-550.	2.5	2
32	Improved risk estimation of locoregional recurrence, secondary contralateral tumors and distant metastases in early breast cancer: the INFLUENCE 2.0 model. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 817-826.	2.5	17
33	Follow-up after breast cancer: Variations, best practices, and opportunities for improvement according to health care professionals. <i>European Journal of Cancer Care</i> , 2021, 30, e13505.	1.5	9
34	Rate and predictors of nodal pathological complete response following neoadjuvant endocrine treatment in clinically biopsy-proven node-positive breast cancer patients. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1928-1933.	1.0	4
35	Impact of the suspension and restart of the Dutch breast cancer screening program on breast cancer incidence and stage during the COVID-19 pandemic. <i>Preventive Medicine</i> , 2021, 151, 106602.	3.4	48
36	Trends in incidence, treatment, survival and subsequent breast cancer in lobular carcinoma in situ in the Netherlands: A population-based analysis. <i>Breast</i> , 2021, 59, 376-382.	2.2	8

#	ARTICLE	IF	CITATIONS
37	Clinicopathologic predictors of early relapse in advanced epithelial ovarian cancer: development of prediction models using nationwide data. <i>Cancer Epidemiology</i> , 2021, 75, 102008.	1.9	0
38	Diagnostics in Patients Suspect for Breast Cancer in The Netherlands. <i>Current Oncology</i> , 2021, 28, 4998-5008.	2.2	0
39	Association between initiation of adjuvant chemotherapy beyond 30 days after surgery and overall survival among patients with triple-negative breast cancer. <i>International Journal of Cancer</i> , 2020, 147, 152-159.	5.1	6
40	Correlation Between Pathologic Complete Response in the Breast and Absence of Axillary Lymph Node Metastases After Neoadjuvant Systemic Therapy. <i>Annals of Surgery</i> , 2020, 271, 574-580.	4.2	72
41	RE: Long-Term Outcomes of Sentinel Lymph Node Biopsy for Ductal Carcinoma in Situ. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa079.	2.9	0
42	From Multiple Quality Indicators of Breast Cancer Care Toward Hospital Variation of a Summary Measure. <i>Value in Health</i> , 2020, 23, 1200-1209.	0.3	7
43	Impact of mammographic screening and advanced cancer definition on the percentage of advanced-stage cancers in a steady-state breast screening programme in the Netherlands. <i>British Journal of Cancer</i> , 2020, 123, 1191-1197.	6.4	8
44	Spatial location of local recurrences after mastectomy: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 263-273.	2.5	26
45	Clinical decision trees support systematic evaluation of multidisciplinary team recommendations. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 355-363.	2.5	5
46	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. <i>American Journal of Human Genetics</i> , 2020, 107, 837-848.	6.2	39
47	Follow-Up Care for Breast and Colorectal Cancer Across the Globe: Survey Findings From 27 Countries. <i>JCO Global Oncology</i> , 2020, 6, 1394-1411.	1.8	24
48	The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands. <i>Journal of Hematology and Oncology</i> , 2020, 13, 147.	17.0	107
49	Assessment of Studies Evaluating Incremental Costs, Effectiveness, or Cost-Effectiveness of Systemic Therapies in Breast Cancer Based on Claims Data: A Systematic Review. <i>Value in Health</i> , 2020, 23, 1497-1508.	0.3	1
50	Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands. <i>Lancet Oncology</i> , The, 2020, 21, 750-751.	10.7	454
51	Adjuvant chemotherapy in small node-negative triple-negative breast cancer. <i>European Journal of Cancer</i> , 2020, 135, 66-74.	2.8	20
52	Evaluating the Age-Based Recommendations for Long-Term Follow-Up in Breast Cancer. <i>Oncologist</i> , 2020, 25, e1330-e1338.	3.7	6
53	De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 725-733.	2.5	19
54	Quantifying the Mitigating Effects of Whole-Breast Radiotherapy and Systemic Treatments on Regional Recurrence Incidence Among Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2020, 27, 3402-3411.	1.5	5

#	ARTICLE	IF	CITATIONS
55	Long-Term Health-Related Quality of Life after Four Common Surgical Treatment Options for Breast Cancer and the Effect of Complications: A Retrospective Patient-Reported Survey among 1871 Patients. <i>Plastic and Reconstructive Surgery</i> , 2020, 146, 1-13.	1.4	52
56	Impact of Older Age and Comorbidity on Locoregional and Distant Breast Cancer Recurrence: A Large Population-Based Study. <i>Oncologist</i> , 2020, 25, e24-e30.	3.7	15
57	Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 423-434.	2.5	14
58	Patients'™ perceptions of 70-gene signature testing: commonly changing the initial inclination to undergo or forego chemotherapy and reducing decisional conflict. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 107-115.	2.5	2
59	Effect of Case-Mix and Random Variation on Breast Cancer Care Quality Indicators and Their Rankability. <i>Value in Health</i> , 2020, 23, 1191-1199.	0.3	9
60	Applying Risk-Based Follow-Up Strategies on the Dutch Breast Cancer Population: Consequences for Care and Costs. <i>Value in Health</i> , 2020, 23, 1149-1156.	0.3	8
61	Breast-conserving therapy in older patients with breast cancer over three decades: progress or stagnation. <i>Journal of Geriatric Oncology</i> , 2019, 10, 330-336.	1.0	0
62	Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients. <i>Annals of Surgery</i> , 2019, 270, 364-372.	4.2	41
63	Improved survival of older patients with advanced breast cancer due to an increase in systemic treatments: a population-based study. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 141-149.	2.5	11
64	Effectiveness of radiotherapy after breast-conserving surgery in older patients with T1-2N0 breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 637-645.	2.5	10
65	Validation of the online prediction model CancerMath in the Dutch breast cancer population. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 665-681.	2.5	4
66	Assessment of Radiotherapy-Associated Angiosarcoma After Breast Cancer Treatment in a Dutch Population-Based Study. <i>JAMA Oncology</i> , 2019, 5, 267.	7.1	37
67	A conditional model predicting the 10-year annual extra mortality risk compared to the general population: a large population-based study in Dutch breast cancer patients. <i>PLoS ONE</i> , 2019, 14, e0210887.	2.5	0
68	An actualised population-based study on the use of radiotherapy in breast cancer patients in the Netherlands. <i>Breast Journal</i> , 2019, 25, 942-947.	1.0	7
69	Facilitating validation of prediction models: a comparison of manual and semi-automated validation using registry-based data of breast cancer patients in the Netherlands. <i>BMC Medical Research Methodology</i> , 2019, 19, 117.	3.1	12
70	Opportunities for personalised follow-up care among patients with breast cancer: A scoping review to identify preference-sensitive decisions. <i>European Journal of Cancer Care</i> , 2019, 28, e13092.	1.5	24
71	Different statistical techniques dealing with confounding in observational research: measuring the effect of breast-conserving therapy and mastectomy on survival. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1485-1493.	2.5	8
72	Breast-Contour-Preserving Procedure as a Multidisciplinary Parameter of Esthetic Outcome in Breast Cancer Treatment in The Netherlands. <i>Annals of Surgical Oncology</i> , 2019, 26, 1704-1711.	1.5	9

#	ARTICLE	IF	CITATIONS
73	Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 217-226.	2.5	38
74	Predicting the risk of locoregional recurrence after early breast cancer: an external validation of the Dutch INFLUENCE-nomogram with clinical cancer registry data from Germany. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1823-1833.	2.5	11
75	Breast Cancer: global quality care optimizing care delivery with existing financial and personnel resources. <i>ESMO Open</i> , 2019, 4, e000861.	4.5	10
76	Prediction and clinical utility of a contralateral breast cancer risk model. <i>Breast Cancer Research</i> , 2019, 21, 144.	5.0	24
77	Immediate Breast Reconstruction in The Netherlands and the United States: A Proof-of-Concept to Internationally Compare Quality of Care Using Cancer Registry Data. <i>Plastic and Reconstructive Surgery</i> , 2019, 144, 565e-574e.	1.4	5
78	Extracapsular extension in the positive sentinel lymph node: a marker of poor prognosis in cT1-2N0 breast cancer patients?. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 711-718.	2.5	5
79	Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study. <i>International Journal of Cancer</i> , 2019, 144, 263-272.	5.1	100
80	Regional Recurrence Risk Following a Negative Sentinel Node Procedure Does Not Approximate the False-Negative Rate of the Sentinel Node Procedure in Breast Cancer Patients Not Receiving Radiotherapy or Systemic Treatment. <i>Annals of Surgical Oncology</i> , 2019, 26, 372-378.	1.5	5
81	Is the incidence of advanced-stage breast cancer affected by whether women attend a steady-state screening program?. <i>International Journal of Cancer</i> , 2018, 143, 842-850.	5.1	23
82	Validation and update of a lymph node metastasis prediction model for breast cancer. <i>European Journal of Surgical Oncology</i> , 2018, 44, 700-707.	1.0	15
83	Responsible Epidemiologic Research Practice: a guideline developed by a working group of the Netherlands Epidemiological Society. <i>Journal of Clinical Epidemiology</i> , 2018, 100, 111-119.	5.0	19
84	Association between body mass index and obesity-related cancer risk in men and women with type 2 diabetes in primary care in the Netherlands: a cohort study (ZODIAC-56). <i>BMJ Open</i> , 2018, 8, e018859.	1.9	20
85	A European, Observational Study of Endocrine Therapy Administration in Patients With an Initial Diagnosis of Hormone Receptor-Positive Advanced Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, e613-e619.	2.4	9
86	Detection and interval cancer rates during the transition from screen-film to digital mammography in population-based screening. <i>BMC Cancer</i> , 2018, 18, 256.	2.6	20
87	Rare cancers in The Netherlands: a population-based study. <i>European Journal of Cancer Prevention</i> , 2018, 27, 384-390.	1.3	8
88	Breast conserving therapy and mastectomy revisited: Breast cancer-specific survival and the influence of prognostic factors in 129,692 patients. <i>International Journal of Cancer</i> , 2018, 142, 165-175.	5.1	115
89	Patients' experiences with decisions on timing of chemotherapy for breast cancer. <i>Breast</i> , 2018, 37, 99-106.	2.2	10
90	Discrepancies Between Surgical Oncologists and Plastic Surgeons in Patient Information Provision and Personal Opinions Towards Immediate Breast Reconstruction. <i>Annals of Plastic Surgery</i> , 2018, 81, 383-388.	0.9	10

#	ARTICLE	IF	CITATIONS
91	What drives centralisation in cancer care?. PLoS ONE, 2018, 13, e0195673.	2.5	26
92	A prediction model for underestimation of invasive breast cancer after a biopsy diagnosis of ductal carcinoma in situ: based on 2892 biopsies and 589 invasive cancers. British Journal of Cancer, 2018, 119, 1155-1162.	6.4	27
93	Risk-based breast cancer follow-up stratified by age. Cancer Medicine, 2018, 7, 5291-5298.	2.8	9
94	Extra-Pulmonary Neuroendocrine Carcinomas: A Population-Based Study in the Netherlands. Neuroendocrinology, 2018, 107, 50-59.	2.5	7
95	Conventional Pathology Versus Gene Signatures for Assessing Luminal A and B Type Breast Cancers: Results of a Prospective Cohort Study. Genes, 2018, 9, 261.	2.4	4
96	Comparison of Logistic Regression and Bayesian Networks for Risk Prediction of Breast Cancer Recurrence. Medical Decision Making, 2018, 38, 822-833.	2.4	31
97	Ten-year conditional recurrence risks and overall and relative survival for breast cancer patients in the Netherlands: Taking account of event-free years. European Journal of Cancer, 2018, 102, 82-94.	2.8	22
98	Variation in treatment and survival of older patients with non-metastatic breast cancer in five European countries: a population-based cohort study from the EURECCA Breast Cancer Group. British Journal of Cancer, 2018, 119, 121-129.	6.4	62
99	Breast MRI increases the number of mastectomies for ductal cancers, but decreases them for lobular cancers. Breast Cancer Research and Treatment, 2017, 162, 353-364.	2.5	39
100	Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years. European Journal of Cancer, 2017, 78, 37-44.	2.8	38
101	Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors. Breast Cancer Research and Treatment, 2017, 164, 133-138.	2.5	12
102	The influence of timing of radiation therapy following breast-conserving surgery on 10-year disease-free survival. British Journal of Cancer, 2017, 117, 179-188.	6.4	38
103	Omitting re-excision for focally positive margins after breast-conserving surgery does not impair disease-free and overall survival. Breast Cancer Research and Treatment, 2017, 164, 157-167.	2.5	37
104	Long-term prognosis of young breast cancer patients (≤ 40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study. BMJ Open, 2017, 7, e017842.	1.9	11
105	Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet a population-based study. Lancet Oncology, The, 2017, 18, 1022-1039.	10.7	285
106	Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptor-Positive Early Breast Cancer: Results of a Prospective Cohort Study. Journal of Clinical Oncology, 2017, 35, 2814-2819.	1.6	31
107	Use of trastuzumab for HER2-positive metastatic breast cancer in daily practice. Anti-Cancer Drugs, 2016, 27, 127-132.	1.4	6
108	Digital vs screen-film mammography in population-based breast cancer screening: performance indicators and tumour characteristics of screen-detected and interval cancers. British Journal of Cancer, 2016, 115, 517-524.	6.4	20

#	ARTICLE	IF	CITATIONS
109	Two decades of external peer review of cancer care in general hospitals; the Dutch experience. <i>Cancer Medicine</i> , 2016, 5, 478-485.	2.8	6
110	10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. <i>Lancet Oncology</i> , The, 2016, 17, 1158-1170.	10.7	301
111	Risk of regional recurrence in triple-negative breast cancer patients: a Dutch cohort study. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 465-472.	2.5	49
112	Sentinel Lymph Node Biopsy and Isolated Tumor Cells in Invasive Lobular Versus Ductal Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, e75-e82.	2.4	7
113	Contemporary Locoregional Recurrence Rates in Young Patients With Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2107-2114.	1.6	45
114	Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in <i>BRCA1/2</i> Mutation Carriers. <i>Journal of Clinical Oncology</i> , 2016, 34, 409-418.	1.6	84
115	Breast-conserving therapy versus mastectomy. <i>Oncoscience</i> , 2016, 3, 304-305.	2.2	4
116	Age and case mix-standardised survival for all cancer patients in Europe 1999-2007: Results of EUROCORE-5, a population-based study. <i>European Journal of Cancer</i> , 2015, 51, 2120-2129.	2.8	66
117	Validity of the BreastConservation! nomogram evaluated. <i>Breast</i> , 2015, 24, 540-542.	2.2	1
118	EUROCOURSE recipe for cancer surveillance by visible population-based cancer RegisTrees® in Europe: From roots to fruits. <i>European Journal of Cancer</i> , 2015, 51, 1050-1063.	2.8	18
119	EUROCOURSE lessons learned from and for population-based cancer registries in Europe and their programme owners: Improving performance by research programming for public health and clinical evaluation. <i>European Journal of Cancer</i> , 2015, 51, 997-1017.	2.8	35
120	Long-term effects of a regional care pathway for patients with rectal cancer. <i>International Journal of Colorectal Disease</i> , 2015, 30, 787-795.	2.2	6
121	Factors influencing time between surgery and radiotherapy: A population based study of breast cancer patients. <i>Breast</i> , 2015, 24, 468-475.	2.2	0
122	Validation of death prediction after breast cancer relapses using joint models. <i>BMC Medical Research Methodology</i> , 2015, 15, 27.	3.1	10
123	Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173 797 patients. <i>BMJ</i> , The, 2015, 351, h4901.	6.0	226
124	Personalisation of breast cancer follow-up: a time-dependent prognostic nomogram for the estimation of annual risk of locoregional recurrence in early breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 627-636.	2.5	48
125	Survival of women with cancers of breast and genital organs in Europe 1999-2007: Results of the EUROCORE-5 study. <i>European Journal of Cancer</i> , 2015, 51, 2191-2205.	2.8	205
126	Survival after Locoregional Recurrence or Second Primary Breast Cancer: Impact of the Disease-Free Interval. <i>PLoS ONE</i> , 2015, 10, e0120832.	2.5	39

#	ARTICLE	IF	CITATIONS
127	External Validity of a Trial Comprised of Elderly Patients With Hormone Receptor-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju051-dju051.	6.3	64
128	Cancer survival in Europe 1999–2007 by country and age: results of EUROCORE-5—a population-based study. <i>Lancet Oncology</i> , The, 2014, 15, 23-34.	10.7	1,554
129	Impact of hospital volume on breast cancer outcome: a population-based study in the Netherlands. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 177-184.	2.5	14
130	Detection of cancer before distant metastasis. <i>BMC Cancer</i> , 2013, 13, 283.	2.6	64
131	A validated web-based nomogram for predicting positive surgical margins following breast-conserving surgery as a preoperative tool for clinical decision-making. <i>Breast</i> , 2013, 22, 773-779.	2.2	44
132	Predictions of survival up to 10 years after diagnosis for European women with breast cancer in 2000–2002. <i>International Journal of Cancer</i> , 2013, 132, 2404-2412.	5.1	69
133	Methodological aspects of estimating rare cancer prevalence in Europe: The experience of the RARECARE project. <i>Cancer Epidemiology</i> , 2013, 37, 850-856.	1.9	21
134	Attending the breast screening programme after breast cancer treatment: A population-based study. <i>Cancer Epidemiology</i> , 2013, 37, 968-972.	1.9	2
135	Breast cancer survival in the US and Europe: A CONCORD high-resolution study. <i>International Journal of Cancer</i> , 2013, 132, 1170-1181.	5.1	100
136	Diverging breast and stomach cancer incidence and survival in migrants in The Netherlands, 1996–2009. <i>Acta Oncologica</i> , 2013, 52, 1195-1201.	1.8	20
137	Do screen-detected breast cancers have positive margins less often than clinically detected breast cancers?. <i>European Journal of Cancer Prevention</i> , 2013, 22, 398-403.	1.3	0
138	Availability of stage at diagnosis, cancer treatment delay and compliance with cancer guidelines as cancer registry indicators for cancer care in Europe: Results of EUROCHIP survey. <i>International Journal of Cancer</i> , 2013, 132, 2910-2917.	5.1	22
139	Progress in Standard of Care Therapy and Modest Survival Benefits in the Treatment of Non-small Cell Lung Cancer Patients in the Netherlands in the Last 20 Years. <i>Journal of Thoracic Oncology</i> , 2012, 7, 291-298.	1.1	53
140	Histological type is not an independent prognostic factor for the risk pattern of breast cancer recurrences. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 271-280.	2.5	26
141	Pattern of follow-up care and early relapse detection in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 859-868.	2.5	40
142	Rare thoracic cancers, including peritoneum mesothelioma. <i>European Journal of Cancer</i> , 2012, 48, 949-960.	2.8	61
143	Disparities in survival of stomach cancer among different socioeconomic groups in North-East Netherlands. <i>Cancer Epidemiology</i> , 2011, 35, 413-416.	1.9	19
144	Breast and stomach cancer incidence and survival in migrants in the Netherlands, 1996–2006. <i>European Journal of Cancer Prevention</i> , 2011, 20, 150-156.	1.3	6

#	ARTICLE	IF	CITATIONS
145	Trends in cervical cancer in the Netherlands until 2007: Has the bottom been reached?. International Journal of Cancer, 2011, 128, 2174-2181.	5.1	46
146	The number of metastatic sites for stage IIIA endometrial carcinoma, endometrioid cell type, is a strong negative prognostic factor. Gynecologic Oncology, 2010, 117, 32-36.	1.4	23
147	Mass screening programmes and trends in cervical cancer in Finland and the Netherlands. International Journal of Cancer, 2008, 122, 1854-1858.	5.1	73
148	Time&space trends in cancer incidence in The Netherlands in 1989&2003. International Journal of Cancer, 2008, 122, 2106-2114.	5.1	16
149	Does lowering the screening age for cervical cancer in The Netherlands make sense?. International Journal of Cancer, 2008, 123, 1403-1406.	5.1	7
150	Geographical relationships between sociodemographic factors and incidence of cervical cancer in the Netherlands 1989&2003. European Journal of Cancer Prevention, 2008, 17, 453-459.	1.3	27
151	Distribution of Inclusions in Neuronal Nuclei and Dystrophic Neurites in Huntington Disease Brain. Journal of Neuropathology and Experimental Neurology, 1999, 58, 129-137.	1.7	85
152	Juvenile Huntington disease in the Netherlands. Pediatric Neurology, 1997, 17, 37-43.	2.1	60
153	Health care professionals' perspectives on shared decision making supported by personalised&risk&for&recurrences&calculations regarding surveillance after breast cancer. European Journal of Cancer Care, 0, , .	1.5	1